PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
32021440-2	2020	Allylated monocarbonyl analogs of curcumin (MACs) have been reported to selectively inhibit a broad range of human cancers including gastric cancer.	Curcumin	34-42	myristoylated alanine rich protein kinase C substrate	Homo sapiens	44-48	
23476444-1	2013	The title compound, C22H21Cl2NO, is a derivative of mono-carbonyl analogues of curcumin (MACs).	Curcumin	79-87	myristoylated alanine rich protein kinase C substrate	Homo sapiens	89-93	
23116317-0	2013	Promising curcumin-based drug design: mono-carbonyl analogues of curcumin (MACs).	Curcumin	10-18	myristoylated alanine rich protein kinase C substrate	Homo sapiens	75-79	
23116317-0	2013	Promising curcumin-based drug design: mono-carbonyl analogues of curcumin (MACs).	Curcumin	65-73	myristoylated alanine rich protein kinase C substrate	Homo sapiens	75-79	
23116317-7	2013	Particularly, the latter called mono-carbonyl analogs of curcumin (MACs) has been reported to has an enhanced stability in vitro and an improved pharmacokinetic profile in vivo.	Curcumin	57-65	myristoylated alanine rich protein kinase C substrate	Homo sapiens	67-71	
23116317-8	2013	Thus, MACs have attracted a high attention for development of new curcumin-based agents with both enhanced bioactivities and pharmacokinetic profiles.	Curcumin	66-74	myristoylated alanine rich protein kinase C substrate	Homo sapiens	6-10